血清胃蛋白酶原比值联合胃泌素-17在早期胃癌诊断中的临床价值

Clinical value of serum pepsinogen combined with gastrin-17 in the diagnosis of early gastric cancer

目的探究血清学检测胃蛋白酶原、胃泌素在胃癌中的诊断价值。方法应用酶联免疫吸附试验检测血清中胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、胃泌素-17(G-17)的值及PGⅠ/PGⅡ比值(PGR),统计分析各指标,评价诊断价值。结果胃癌组PGⅠ、PGⅡ、G-17水平较正常组下降;进展期胃癌组的PGⅠ、PGR水平较正常组下降,PGⅡ水平上升。G-17筛查胃癌的最佳临界值为G-17<3.25 pmol/l,灵敏度和特异度分别为69.29%和94.14%。PGR筛查进展期胃癌的最佳临界值为PGR<7.11,灵敏度和特异度为43.84%和99.01%。结论血清学检测胃蛋白酶原、胃泌素可以作为筛查胃癌及进展期胃癌的指标。

Objective To explore the serological detection value of pepsinogeo and gastrin in the diagnosis Of gastric cancer. Methods The levels of pepsinogen I（PGI）, gastrin17（ G17 ） and PGI/PGII ratio（PGR） were measured by enzyme -linked immunosorbent assay （ELISA）. The indicators were conducted for statistical analysis to evaluate the diagnostic value. Results The levels of PGI, PG 11 and G 17 in gastric cancer group decreased compared with that in control group. The levels of PGⅠ and PGR in progressive gastric cancer group decreased compared with control group,but PG level in,creased. The best cut off valueof G 17 screening for gastric cancer was G 17 〈 3.25 pmol/1, stmsitivsity god specificity was respectively 69.29% and 94. 14%. And that for advanced gastriccancer was PGR 〈 7.11, sensitivity and specificity was pesctively 43.84% and 99.01%. Conclusion Serological detection of pepsinogen, gastrin can be used as a screening indicator for gastrie cancer and progressive gastric cancer.